Agilon Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Agilon Health, Inc. on November 5, 2025. The filing addresses a regulatory notice received from the New York Stock Exchange (NYSE) regarding the Company's compliance with continued listing standards.
Key Financial Metrics
This filing does not contain specific financial statements, revenue figures, profit data, cash flow metrics, or debt levels. The only quantitative metric disclosed is the Company's stock price performance, which triggered the regulatory notice.
Material Changes and Events
- NYSE Delisting Notice: On November 5, 2025, the Company received written notice from the NYSE stating it is no longer in compliance with Section 802.01C of the NYSE Listed Company Manual.
- Reason for Non-Compliance: The average closing price of the Company's common stock was less than $1.00 per share over a consecutive 30 trading-day period ended November 4, 2025.
- Compliance Timeline: The Company has a six-month cure period to regain compliance. It plans to notify the NYSE by November 19, 2025, of its intent to remain listed.
Outlook, Management Commentary, and Risks
Proposed Remedy: The Company anticipates pursuing a reverse stock split to regain compliance. This action is subject to stockholder approval, which the Company expects to seek at its annual general meeting in 2026.
Regulatory Pathway: Under NYSE rules, if the Company obtains stockholder approval for a reverse stock split by its next annual meeting, the price condition will be deemed cured if the share price promptly exceeds $1.00 per share following implementation and remains above that level for at least 30 trading days.
Risk Factors: The filing includes extensive forward-looking statements and risk disclosures, including:
- History of net losses and expected future expense increases.
- Uncertainty regarding the ability to secure additional capital.
- Risks related to management transitions, including the search for a permanent CEO.
- Dependence on Medicare Advantage payors and physician partners.
- Potential for medical expenses to exceed revenues.
Investor Verification Checklist
- Verify the current trading price of Agilon Health (AGL) to assess the severity of the price deficiency.
- Monitor the Company's announcement by November 19, 2025, regarding its formal intent to remain listed.
- Review the proposed reverse stock split ratio and terms when presented to stockholders.
- Confirm the date of the 2026 annual general meeting for the stockholder vote.
- Examine the most recent Form 10-K for detailed financial health, liquidity, and debt obligations not included in this 8-K.